Welcome to our dedicated page for HNSA news (Ticker: HNSA), a resource for investors and traders seeking the latest updates and insights on HNSA stock.
Hansa Biopharma (HNSA) is a leader in developing IgG-cleaving enzyme therapies for complex immunological challenges. This page provides essential updates on clinical advancements, regulatory milestones, and strategic initiatives across transplantation, autoimmune diseases, and gene therapy applications.
Investors and researchers will find comprehensive coverage of HNSA's progress with IDEFIRIX commercialization, next-generation candidates like HNSA-5487, and pivotal trials addressing anti-GBM disease and transplant desensitization. Our curated news collection enables efficient tracking of scientific breakthroughs and market developments.
Key updates include clinical trial results, partnership announcements with gene therapy innovators, financial performance reports, and regulatory submissions. All content is verified through primary sources to ensure accuracy and current relevance.
Bookmark this page for structured access to HNSA's evolving therapeutic pipeline and scientific leadership in antibody-mediated conditions. Regular updates reflect the company's commitment to transforming treatment paradigms through targeted enzyme technology.
Hansa Biopharma (NASDAQ Stockholm: HNSA) announced it will publish its interim report for January-June 2024 on July 18, 2024. The company will host a quarterly conference call on the same day at 14:00 CEST/8:00 AM EST, featuring presentations from key executives including CEO Søren Tulstrup and CFO Evan Ballantyne. The call will provide a comprehensive review of the interim results along with a business and pipeline update. The event will be conducted in English, and presentation slides will be available on the Hansa Biopharma website.
Interested participants can join the call using the provided dial-in details for Sweden, the UK, and the US, or access the live webcast through the company's event webpage.
Hansa Biopharma has increased its registered share capital and the number of shares and votes. The company issued 2,305,260 new ordinary shares, raising the number of votes by the same amount and increasing the share capital by SEK 2,305,260.
Additionally, all 2,362,445 issued class C shares were converted into ordinary shares to deliver ordinary shares to participants in Hansa's incentive programs and to cover social contributions resulting from these programs.
As of June 28, 2024, Hansa Biopharma's total number of registered shares stands at 67,814,241, all of which are ordinary shares. Correspondingly, the number of votes also totals 67,814,241, and the registered share capital amounts to SEK 67,814,241.
Hansa Biopharma (HNSA) has completed the randomization phase in its pivotal Phase 3 US ConfIdeS trial. This trial evaluates the efficacy of imlifidase in kidney transplantation for highly sensitized patients. The trial involves 64 patients and is conducted across 24 US sites. The primary endpoint is kidney graft function at 12 months, measured by eGFR. Data from this trial will support a Biologic License Application (BLA) to the FDA, expected in H2 2025. Imlifidase, already conditionally approved in Europe under IDEFIRIX® for similar indications, is also being explored for autoimmune diseases and as a pre-treatment in gene therapy.
Hansa Biopharma (NASDAQ: HNSA) announced it will present data on its antibody-cleaving enzyme imlifidase at the 2024 American Transplant Congress (ATC). Imlifidase targets IgG and inhibits the IgG-mediated immune response, aiding highly sensitized kidney transplant patients. Key presentations include the reestablishment of COVID-specific IgG antibodies and long-term clinical outcomes of imlifidase. Hansa has conditional European approval for imlifidase under the name IDEFIRIX® and plans to submit a Biologic License Application to the US FDA in 2025. The enzyme is also being studied for pre-treating gene therapy in rare diseases and certain autoimmune conditions.
